Citations

Showing 10 of 108094 citations.

Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance
Ye, Zhenqing, Li, Ying , Leong, Hon S. , Eckel‐Passow, Jeanette E. , Kocher, Jean‐Pierre , Wang, Liguo , Leong, Hon Sing, Eckel-Passow, Jeanette, Leong, Hon S , Wang, Liguo , Dong, Haidong , Ma, Tao , Huang, Haojie , Liang, Han

Mayo Clinic

Clinical Cancer Research | April 4, 2018 | Volume: 24 | Issue: 14 | Pages: 3299-3308

10.1158/1078-0432.ccr-17-3008 | PMID 29618619 Get It

Abstract Purpose: Homozygous deletions play important roles in carcinogenesis. The genome-wide screening for homozygously deleted genes in many different cancer types with a large number of patient specimens representing the tumor heterogeneity has not been done. Experimental Design: We performed integrative analyses of the copy-number profiles of 10,759 patients across 31 cancer types from The Cancer Genome Atlas project. Results: We found that the type-I interferon, α-, and β-defensin genes were homozygously deleted in 19 cancer types with high frequencies (7%–31%, median = 12%; interquartile range = 10%–16.5%). Patients with homozygous deletion of interferons exhibited significantly shortened overall or disease-free survival time in a number of cancer types, whereas patients with homozygous deletion of defensins did not significantly associate with worse overall or disease-free survival. Gene expression analyses suggested that homozygous deletion of interferon and defensin genes could activate genes involved in oncogenic and cell-cycle pathways but repress other genes involved in immune response pathways, suggesting their roles in promoting tumorigenesis and helping cancer cells evade immune surveillance. Further analysis of the whole exomes of 109 patients with melanoma demonstrated that the homozygous deletion of interferon (P = 0.0029, OR = 11.8) and defensin (P = 0.06, OR = 2.79) genes are significantly associated with resistance to anti-CTLA4 immunotherapy. Conclusions: Our analysis reveals that the homozygous deletion of interferon and defensin genes is prevalent in human cancers, and importantly this feature can be used as a novel prognostic biomarker for immunotherapy resistance. Clin Cancer Res; 24(14); 3299–308. ©2018 AACR.
Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol
Awada, Ahmad , O’Shaughnessy, Joyce , Twelves, Chris , Im, Seock‐Ah , Hannah, Alison L., Lü, Lin , Sy, Sherwin K. B. , Caygill, Katie, Zajchowski, Deborah A., Davis, Darren W. , Tagliaferri, Mary , Hoch, Ute , Perez, Edith A. , Im, Seock-Ah , Awada, Ahmad , Rugo, Hope S. , Cortés, Javier

Mayo Clinic

Clinical Cancer Research | April 4, 2018 | Volume: 24 | Issue: 14 | Pages: 3348-3357

10.1158/1078-0432.ccr-17-3059 | PMID 29618616 Get It

Abstract Purpose: Preplanned exploratory analyses were performed to identify biomarkers in circulating tumor cells (CTC) predictive of response to the topoisomerase 1 inhibitor etirinotecan pegol (EP). Experimental Design: The BEACON trial treated patients with metastatic breast cancer (MBC) with EP or treatment of physician's choice (TPC). Blood from 656 of 852 patients (77%) was processed with ApoStream to enrich for CTCs. A multiplex immunofluorescence assay measured expression of candidate response biomarkers [topoisomerase 1 (Top1), topoisomerase 2 (Top2), Ki67, RAD51, ABCG2, γH2AX, and terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL)] in CTCs. Patients were classified as Top1 low (Top1Lo) or Top1 high (Top1Hi) based on median CTC Top1 expression. Correlation of CTC biomarker expression at baseline, cycle 2 day 1 (C2D1), and cycle 4 day 1 with overall survival (OS) was investigated using Cox regression and Kaplan–Meier analyses. Results: Overall, 98% of samples were successfully processed, of which 97% had detectable CTCs (median, 47–63 CTCs/mL; range, 0–2,020 CTCs/mL). Top1, Top2, and TUNEL expression was detected in 52% to 90% of samples; no significant associations with OS were observed in pretreatment samples for either group. EP-treated patients with low C2D1Top1+ CTCs had improved OS compared with those with higher positivity (14.1 months vs. 11.0 months, respectively; HR, 0.7; P = 0.02); this difference was not seen in TPC-treated patients (HR, 1.12; P = 0.48). Patients whose CTCs decreased from Top1Hi to Top1Lo at C2D1 had the greatest OS benefit from EP (HR, 0.57; P = 0.01). Conclusions: CTC Top1 expression following EP treatment may identify patients with MBC most likely to have an OS benefit. Clin Cancer Res; 24(14); 3348–57. ©2018 AACR.
Experience With Mixed Infections of Plasmodium Falciparum and Vivax
Miller, Monte B., Bratton, Jack L., Hanson, John, Cohen, Morris A. , Reynolds, Ralph D., Hunt, John S., Jilek, Dennis, Lohr, David C.

Mayo Clinic

Military Medicine | April 4, 2018 | Volume: 138 | Issue: 9 | Pages: 567-587

10.1093/milmed/138.9.567 Get It

Physiology in Perspective: Seeking Solutions to Biological Questions
Sieck, Gary C.

Mayo Clinic

Physiology | April 4, 2018 | Volume: 33 | Issue: 3 | Pages: 168-169

10.1152/physiol.00010.2018 | PMID 29616879 Get It

To the Soldier Medic
Bowen, Thos. E., Learmonth, James

Mayo Clinic

Military Medicine | April 4, 2018 | Volume: 156 | Issue: 11 | Pages: 638-639

10.1093/milmed/156.11.638 Get It

Novel Measure of Local Impedance Predicts Catheter–Tissue Contact and Lesion Formation
Sulkin, Matthew S. , Laughner, Jacob I. , Hilbert, Sebastian , Kosiuk, Jędrzej , Younan, Paul, Romero, Iñaki , Shuros, Allan, Hamann, Jason J., Hindricks, Gerhard , Kapa, Suraj , Bollmann, Andreas, Bollmann, Andreas

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 4, 2018 | Volume: 11 | Issue: 4 | Pages: No page available

10.1161/circep.117.005831 | PMID 29618475 Get It

Background: Coupling between the ablation catheter and myocardium is critical to resistively heat tissue with radiofrequency ablation. The objective of this study was to evaluate whether a novel local impedance (LI) measurement on an ablation catheter identifies catheter–tissue coupling and is predictive of lesion formation. Methods and Results: LI was studied in explanted hearts (n=10 swine) and in vivo (n=10; 50–70 kg swine) using an investigational electroanatomic mapping system that measures impedance from an ablation catheter with mini-electrodes incorporated in the distal electrode (Rhythmia and IntellaNav MiFi OI, Boston Scientific). Explanted tissue was placed in a warmed (37 °C) saline bath mounted on a scale, and LI was measured 15 mm away from tissue to 5 mm of catheter–tissue compression at multiple catheter angles. Lesions were created with 31 and 50 W for 5 to 45 seconds (n=90). During in vivo evaluation of LI, measurements of myocardium (n=90) and blood pool (n=30) were guided by intracardiac ultrasound while operators were blinded to LI data. Lesions were created with 31 and 50 W for 45 seconds in the ventricles (n=72). LI of myocardium (119.7 Ω) was significantly greater than that of blood pool (67.6 Ω; P <0.01). Models that incorporate LI drop (ΔLI) to predict lesion size had better performance than models that incorporate force-time integral ( R 2 =0.75 versus R 2 =0.54) and generator impedance drop ( R 2 =0.82 versus R 2 =0.58). Steam pops displayed a significantly higher starting LI and larger ΔLI compared with successful radiofrequency applications ( P <0.01). Conclusions: LI recorded from miniature electrodes provides a valuable measure of catheter–tissue coupling, and ΔLI is predictive of lesion formation during radiofrequency ablation.
Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system
Linninger, Andreas A. , Hartung, Grant , Liu, Benjamin P. , Mirkov, Snezana, Tangen, Kevin, Lukas, Rimas V. , Unruh, Dusten , James, C. David , Sarkaria, Jann N. , Horbinski, Craig

Mayo Clinic

Neuro-Oncology | April 4, 2018 | Volume: 20 | Issue: 9 | Pages: 1197-1206

10.1093/neuonc/noy051 | PMID 29660019 Get It

PositivePneumocystis jiroveciiSputum PCR Results with Negative Bronchoscopic PCR Results in Suspected Pneumocystis Pneumonia
Pennington, Kelly M. , Wilson, John , Escalante, Patricio , Escalante, Patricio , Limper, Andrew H.

Mayo Clinic

Canadian Respiratory Journal | April 3, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-5

10.1155/2018/6283935 | PMID 29849833 Get It

Introduction. The diagnostic standard forPneumocystis jiroveciipneumonia (PCP) is direct microscopic identification; however, in recent years, polymerase chain reaction (PCR) from bronchoalveolar lavage (BAL) samples to detectPneumocystisnucleic acids has proven to be more sensitive and specific. Sputum samples have been presumed inferior to bronchoscopic samples secondary to variability and adequacy of sample collection. We observed several cases of positive sputum PCP-PCR results with negative PCP-PCR BAL results. The aim of the current study was to further characterize the clinical setting and outcomes in patients with positive sputum PCP-PCR samples and negative BAL PCP-PCR samples.Methods. We identified all patients who underwentP. jirovecii-PCR testing at Mayo Clinic between 2011 and 2016. Patients with a positive sputum and negative BAL sample collected within a 14-day time frame were identified and underwent further chart review for demographics, immunocompromised state, and clinical outcome.Results. From 2011 to 2016, 4431 respiratory samples from 3021 unique patients were tested for the presence ofP. jiroveciiby PCR. Fifty-five samples (1.2% of all samples collected) belonging to 24 unique patients (0.79% of patients tested) were identified as having a positive and negative sample collected within 14 days. Of these 24 patients, 10 (46%) patients had a positive sputum or tracheal secretion sample with negative BAL or bronchial washings. Out of these 10 patients, 8 were immunocompromised and 9 underwent treatment for PCP with 6 patients improving.Conclusion. Our results suggest that discordantP. jirovecii-PCR testing results from sputum and bronchoscopic specimens are an infrequent occurrence. Patients with positiveP. jirovecii-PCR sputum/tracheal secretion samples and negative bronchoscopic samples appear to be clinically infected and respond to PCP treatment. SputumP. jirovecii-PCR testing may be a viable alternative to invasive testing.
Improving Long-Term Outcomes for Patients with Extra-Abdominal Soft Tissue Sarcoma Regionalization to High-Volume Centers, Improved Compliance with Guidelines or Both?
Bagaria, Sanjay P. , Chang, Yu‐Hui , Gray, Richard J. , Ashman, Jonathan B. , Attia, Steven , Wasif, Nabil , Bagaria, Sanjay P , Chang, Yu-Hui

Mayo Clinic

Sarcoma | April 3, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-10

10.1155/2018/8141056 | PMID 29849479 Get It

Introduction. Optimization of outcomes of extra-abdominal STS is not clearly understood. We sought to determine whether hospital surgical volume and adherence to NCCN guidelines, or both, are associated with outcomes in the treatment of extra-abdominal soft tissue sarcoma (STS).Methods. The National Cancer Database (NCDB) was queried for patients undergoing surgery for extra-abdominal STS diagnosed from 2003 to 2007. Mean annual hospital volume for STS surgery was divided into volume terciles (1T ≤3, 2T 4–10, and 3T ≥11 cases/year). Adherence to NCCN guidelines was determined. Primary outcome was overall survival.Results. Our study population consisted of 13,684 patients with a median age of 56 years. 3T hospitals were more likely to adhere to NCCN guidelines for stage III patients (63% versus 47%;p≤0.001) than 1T hospitals. On multivariable analysis, adherence to NCCN guidelines was associated with improved survival (HR = 0.79, CI 0.73–0.87;p<0.001), but hospital volume was not (3T versus 1T: HR = 0.92, CI 0.82–1.02;p=0.12). Five-year overall survival was comparable for compliant groups at 1T, 2T, and 3T hospitals (72%, 72.4%, and 72.6%, resp.). 3T hospitals were not associated with a lower risk of 30-day mortality (OR 0.70, 95% CI 0.44–1.11) compared to 1T hospitals but did have a higher R0 resection rate (OR 1.43, 95% CI 1.32–1.54).Conclusions. Adherence to NCCN guidelines, irrespective of hospital volume, is associated with improved overall survival for patients with extra-abdominal STS. High-volume hospitals more often adhere to guidelines, but low-volume hospitals that follow national guidelines may achieve comparable outcomes.
Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series
Rizvi, Mahrukh, Trivedi, Vrinda, Nasim, Faria, Lin, Erica , Andrijasevic, Nicole, Gajić, Ognjen, Rizvi, Mahrukh S, Kashyap, Rahul , Gajic, Ognjen

Mayo Clinic

Critical Care Medicine | April 3, 2018 | Volume: 46 | Issue: 7 | Pages: e628-e633

10.1097/ccm.0000000000003121 | PMID 29613861 Get It

Objectives: Midodrine is an oral alpha-agonist approved for orthostatic hypotension. The use of midodrine as a vasopressor sparing agent has steadily increased in the ICU despite limited evidence for its safety in that setting. We describe the trends in use and reported side effects and complications of midodrine in multidisciplinary ICUs of a tertiary care institution. Design: Single-center retrospective case series. Setting: Medical and surgical ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester. Patients: Adult patients admitted to any ICU who received midodrine for hypotension were eligible. Interventions: None. Measurements and Main Results: We reviewed the mean arterial pressures and cumulative vasopressor dose before and after midodrine administration and assessed for reported complications. During the study period, a total of 1,119 patients were initiated on midodrine, 56% in surgical ICUs, 42% in medical ICUs, and 2% in a mixed medical and surgical neurology ICU. There was a significant decrease in the number of patients on vasopressors 24 hours after initiation of midodrine (663 to 344; p < 0.001); among the patients that remained on vasopressors, there was a significant decrease in the median cumulative vasopressor dose (p = 0.002). There was a significant increase in median mean arterial pressure 24 hours after initiation of midodrine among patients who were not on vasopressors (65–68; p < 0.01). Asymptomatic bradycardia (heart rate < 50 beats/min) was the most common side effect (n = 172 patients, median 39 beats/min). Two patients developed bowel ischemia after initiation of midodrine that prompted discontinuation of midodrine in one case. Evaluating trends of utilization, the off-label use of midodrine has increased steadily over the years across ICUs. Conclusions: Our results suggest that midodrine is being increasingly used as an adjunct to increase mean arterial pressure and facilitate weaning of vasopressors in the ICU. Prospective trials are required to further establish the appropriate timing, efficacy, safety, and cost-effectiveness of midodrine use in ICU patients.